Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Role of Vitamin K on Knee Osteoarthritis Outcomes
Sponsor: Boston University
Summary
The appropriate form and dosing of vitamin K to benefit relevant outcomes in knee osteoarthritis (OA) are not known. In intervention studies for conditions other than knee OA (e.g., prevention of cardiovascular disease), the most commonly used forms and doses include phylloquinone (vitamin K1; 1000µg or 500µg daily) or menaquinone-7 (MK-7 or vitamin K2; 300µg daily). However, whether these doses are adequate to increase vitamin K to levels that ameliorate risk of adverse OA outcomes is not known. Furthermore, although some studies suggest enhanced bioavailability of MK-7 over vitamin K1, as well as extra-hepatic effects, whether this is relevant for an older population with knee OA is not known, The overall goal of this pilot randomized clinical trial (RCT) is to test different subtypes and doses of vitamin K supplementation in older adults with knee OA and to measure changes in relevant biochemical measures.
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
55
Start Date
2025-06-03
Completion Date
2026-12
Last Updated
2026-01-23
Healthy Volunteers
No
Conditions
Interventions
Vitamin K1 500 µg
One pill daily for 4 weeks.
K1 1000 µg
One pill daily for 4 weeks.
Vitamin K2 (MK-7) 300 µg
One pill daily for 4 weeks.
Placebo
Placebo pill daily for 4 weeks.
Locations (1)
Boston Medical Center, Rheumatology Clinic
Boston, Massachusetts, United States